The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Intratumoral Ral-binding protein 1 (RalBP1) expression as a potential predictor of bevacizumab treatment efficacy in patients with ovarian cancer.
 
Fabian Bernhard Thaddäus Kraus
No Relationships to Disclose
 
Christina Schramm
No Relationships to Disclose
 
Doris Mayr
No Relationships to Disclose
 
Anca Chelariu-Raicu
No Relationships to Disclose
 
Juliane Reichenbach
No Relationships to Disclose
 
Nicole Elisabeth Topalov
No Relationships to Disclose
 
Christina Viktoria Tauber
Research Funding - SAGA Diagnostics
 
Alexander Burges
Honoraria - AstraZeneca; Roche; Tesaro/GSK
 
Mirjana Kessler
No Relationships to Disclose
 
Sven Mahner
Honoraria - AstraZeneca; Clovis Oncology; GlaxoSmithKline; Janssen-Cilag; Jenapharm; Medac; Novartis/Pfizer; PharmaMar; Roche/Genentech; Teva
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Immunogen; Janssen-Cilag; Medac; Merck Sharp & Dohme; Roche; Sensor-Kinesis Corp.; Tesaro
Research Funding - AstraZeneca; Bayer; Boehringer Ingelheim; GlaxoSmithKline; Janssen-Cilag; Medac; PharmaMar; Roche; Tesaro
 
Fabian Trillsch
Honoraria - AstraZeneca; Eisai; MSD Oncology; Tesaro/GSK
Consulting or Advisory Role - AstraZeneca; Eisai Germany; Immunogen; MSD Oncology; Tesaro/GSK
Research Funding - AstraZeneca (Inst); SAGA Diagnostics (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Immunogen; Tesaro/GSK
 
Bastian Czogalla
Honoraria - AstraZeneca